Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Viracta Therapeutics : Evercore ISI Starts Viracta Therapeutics at Outperform with $45 Price Target

03/25/2021 | 10:24am EST


ę MT Newswires 2021
All news about VIRACTA THERAPEUTICS, INC.
01/04Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
PR
2021VIRACTA THERAPEUTICS, INC.(NASDAQGS : VIRX) added to NASDAQ Biotechnology Index
CI
2021Viracta Therapeutics to be Added to the Nasdaq Biotechnology Index
PR
2021Viracta Therapeutics Presents Preclinical Vecabrutinib Data in Oral and Poster Presenta..
CI
2021Viracta Says Epstein-Barr Therapy Had 40% Overall Response Rate in Trial; Shares Fall
MT
2021Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Sign..
CI
2021INSIDER SELL : Viracta Therapeutics
MT
2021Viracta Therapeutics Secures FDA Orphan Drug Designation for Lymphoma Combo Therapy
MT
2021Viracta Therapeutics Gets FDA Orphan Drug Designation for Nana-val
DJ
2021Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral ..
PR
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Capitalization 118 M 118 M -
EV / Sales 2020
Capi. / Sales 2021 -
Nbr of Employees 24
Free-Float 85,2%
Chart VIRACTA THERAPEUTICS, INC.
Duration : Period :
Viracta Therapeutics, Inc. Technical Analysis Chart | VIRX | US92765F1084 | MarketScreener
Technical analysis trends VIRACTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,17 $
Average target price 33,50 $
Spread / Average Target 957%
EPS Revisions
Managers and Directors
Ivor Royston President, Chief Executive Officer & Director
Daniel R. Chevallard Secretary, Chief Operating & Financial Officer
Roger J. Pomerantz Chairman
Lisa Rojkjaer Chief Medical Officer
Ayman El-Guindy Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
VIRACTA THERAPEUTICS, INC.-13.15%118
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684